Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue 2, 2011, Pages 136-145

  Kang, Hye J ^a   Lee, Seung S ^a   Kim, Kyeong M ^b   Choi, Tae H ^b   Cheon, Gi J ^a   Kim, Won S ^c   Suh, Cheolwon ^d   Yang, Sung H ^a   Lim, Sang M ^a  

^a Korea Cancer Center Hospital   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

131I rituximab; B cell non Hodgkin's lymphoma; Radioimmunotherapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KOREA; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOIMMUNOTHERAPY;

EID: 79956105591     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01393.x     Document Type: Article

References (17)

1. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1023-30.
2. Marcus R, Imrie K, Solal-Celigny P etal. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579-86.
3. Pfreundschuh M, Trümper L, Osterborg A etal. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.
4. Press OW. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Semin Oncol 2003; 30: 10-21.
5. Kaminski MS, Zelenetz AD, Press OW etal. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19: 3918-28.
6. Witzig TE, Gordon LI, Cabanillas F etal. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-63.
7. Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 4418-25.
8. Cheson BD, Horning SJ, Coiffier B etal. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-53.
9. Common terminology criteria for adverse events, version 3.0. 2003. [Cited 29 March 2011.] Available from URL:
10. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-46.
11. Kaminski MS, Zasadny KR, Francis IR etal. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459-65.
12. Witzig TE, White CA, Wiseman GA etal. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-803.
13. Knox SJ, Goris ML, Trisler K etal. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2: 457-70.
14. Scheidhauer K, Wolf I, Baumgartl HJ etal. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002; 29: 1276-82.
15. Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003; 18: 513-24.
16. Juweid ME. Radioimmunotherapy with 131I-rituximab: what we know and what we don't know. Cancer Biother Radiopharm 2003; 18: 489-95.
17. Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F etal. Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. Leuk Lymphoma 2010; 51: 399-405.